• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728).
  

PubMed=2583869; DOI=10.1002/ijc.2910440525
Brothman A.R., Lesho L.J., Somers K.D., Wright G.L. Jr., Merchant D.J.
Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma.
Int. J. Cancer 44:898-903(1989)

PubMed=2016798; DOI=10.1016/S0022-5347(17)38540-3
Brothman A.R., Wilkins P.C., Sales E.W., Somers K.D.
Metastatic properties of the human prostatic cell line, PPC-1, in athymic nude mice.
J. Urol. 145:1088-1091(1991)

PubMed=8616865
Murakami Y.S., Albertsen H., Brothman A.R., Leach R.J., White R.L.
Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10.
Cancer Res. 56:2157-2160(1996)

PubMed=11304728; DOI=10.1002/pros.1045
van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.
Widely used prostate carcinoma cell lines share common origins.
Prostate 47:36-51(2001)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)